Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report

被引：4

作者：

Vo, Kim ^{[1
]}

Guan, Tiffany ^{[1
]}

Banerjee, Rahul ^{[2
]}

Lo, Mimi ^{[1
]}

Young, Rebecca ^{[1
]}

Shah, Nina ^{[2
]}

机构：

[1] Univ Calif San Francisco, Dept Pharmaceut Serv, Med Ctr, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2022年 / 28卷 / 05期

关键词：

plasma cell leukemia; venetoclax; multiple myeloma; stem cell transplantation; MYELOMA; TRANSPLANTATION; COMBINATION; BORTEZOMIB;

D O I：

10.1177/10781552221074269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction Plasma cell leukemia (PCL) is a rare but aggressive variant of multiple myeloma (MM) with a poor prognosis. Due to the limited number of prospective clinical trials studying PCL, treatment options are often extrapolated from data available for the treatment of MM. Venetoclax has recently demonstrated antimyeloma activity in patients with relapsed/refractory MM carrying the t(11;14) translocation. However, few cases have reported the analogous efficacy of venetoclax in PCL. Case Report A 64-year-old Caucasian male developed relapsed PCL despite treatment with hyperCD (hyperfractionated cyclophosphamide and dexamethasone) and Dara-KRd (daratumumab, carfilzomib, lenalidomide, dexamethasone). Due to the refractory nature of his disease and the presence of a t(11:14) translocation, the patient was subsequently initiated on venetoclax 400 mg daily and dexamethasone 4 mg once weekly. Management and outcome The patient achieved a complete response by International Myeloma Working Group criteria three months after initiating venetoclax-dexamethasone, including a repeat bone marrow biopsy that showed no abnormal plasma cells. He successfully underwent consolidation with melphalan-based autologous stem cell transplantation. He remains disease-free 9 months after venetoclax initiation. Discussion Combination all-oral therapy with venetoclax and dexamethasone can induce deep hematologic responses in patients with relapsed/refractory PCL carrying the t(11;14) translocation.

引用

页码：1244 / 1248

页数：5

共 19 条

[11] Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research [J].

Mahindra, A. ;

Kalaycio, M. E. ;

Vela-Ojeda, J. ;

Vesole, D. H. ;

Zhang, M-J ;

Li, P. ;

Berenson, J. R. ;

Bird, J. M. ;

Dispenzieri, A. ;

Gajewski, J. L. ;

Gale, R. P. ;

Holmberg, L. ;

Kumar, S. ;

Kyle, R. A. ;

Lazarus, H. M. ;

Lonial, S. ;

Mikhael, J. ;

Milone, G. A. ;

Munker, R. ;

Nath, R. ;

Saccaro, S. ;

To, L. Bik ;

Vogl, D. T. ;

Wirk, B. ;

Hari, P. .

LEUKEMIA, 2012, 26 (05) :1091-1097

[12] Plasma cell leukemia: update on biology and therapy [J].

Mina, Roberto ;

D'Agostino, Mattia ;

Cerrato, Chiara ;

Gay, Francesca ;

Palumbo, Antonio .

LEUKEMIA & LYMPHOMA, 2017, 58 (07) :1538-1547

[13] Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT [J].

Morris, Curly ;

Iacobelli, Simona ;

Gahrton, Gosta ;

Garderet, Laurent ;

Drake, Mary ;

van Biezen, Anja ;

Mohty, Mohamad ;

Blaise, Didier ;

Poire, Xavier ;

Kersten, Marie Jose ;

Milpied, Noel-Jean ;

Lenhoff, Stig ;

Russell, Nigel H. ;

Finke, Juergen ;

de Witte, T. M. .

BLOOD, 2011, 118 (21) :877-877

[14] Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia [J].

Musto, P. ;

Simeon, V. ;

Martorelli, M. C. ;

Petrucci, M. T. ;

Cascavilla, N. ;

Di Raimondo, F. ;

Caravita, T. ;

Morabito, F. ;

Offidani, M. ;

Olivieri, A. ;

Benevolo, G. ;

Mina, R. ;

Guariglia, R. ;

D'Arena, G. ;

Mansueto, G. ;

Filardi, N. ;

Nobile, F. ;

Levi, A. ;

Falcone, A. ;

Cavalli, M. ;

Pietrantuono, G. ;

Villani, O. ;

Bringhen, S. ;

Omede, P. ;

Lerose, R. ;

Agnelli, L. ;

Todoerti, K. ;

Neri, A. ;

Boccadoro, M. ;

Palumbo, A. .

LEUKEMIA, 2014, 28 (01) :222-225

[15] The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia [J].

Nalghranyan, Sos ;

Singh, Amrit P. ;

Schinke, Carolina .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (02) :E34-E35

[16] Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma [J].

Ravi, Praful ;

Kumar, Shaji K. ;

Roeker, Lindsey ;

Gonsalves, Wilson ;

Buadi, Francis ;

Lacy, Martha Q. ;

Go, Ronald S. ;

Dispenzieri, Angela ;

Kapoor, Prashant ;

Lust, John A. ;

Dingli, David ;

Lin, Yi ;

Russell, Stephen J. ;

Leung, Nelson ;

Gertz, Morie A. ;

Kyle, Robert A. ;

Bergsagel, P. Leif ;

Rajkumar, S. Vincent .

BLOOD CANCER JOURNAL, 2018, 8

[17] Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome [J].

Royer, Bruno ;

Minvielle, Stephane ;

Diouf, Momar ;

Roussel, Murielle ;

Karlin, Lionel ;

Hulin, Cyrille ;

Arnulf, Bertrand ;

Macro, Margaret ;

Cailleres, Sylvie ;

Brion, Annie ;

Brechignac, Sabine ;

Belhadj, Karim ;

Chretien, Marie Lorraine ;

Wetterwald, Marc ;

Chaleteix, Carine ;

Tiab, Mourad ;

Leleu, Xavier ;

Frenzel, Laurent ;

Garderet, Laurent ;

Choquet, Sylvain ;

Fuzibet, Jean Gabriel ;

Dauriac, Charles ;

Fornecker, Luc-Matthieu ;

Benboubker, Lotfi ;

Facon, Thierry ;

Moreau, Philippe ;

Avet-Loiseau, Herve ;

Marolleau, Jean Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) :2125-+

[18] Genetic aberrations and survival in plasma cell leukemia [J].

Tiedemann, R. E. ;

Gonzalez-Paz, N. ;

Kyle, R. A. ;

Santana-Davila, R. ;

Price-Troska, T. ;

Van Wier, S. A. ;

Chng, W. J. ;

Ketterling, R. P. ;

Gertz, M. A. ;

Henderson, K. ;

Greipp, P. R. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Rajkumar, S. V. ;

Bergsagel, P. L. ;

Stewart, A. K. ;

Fonseca, R. .

LEUKEMIA, 2008, 22 (05) :1044-1052

[19] Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review [J].

Valliani, Salimah ;

Ali, Mir ;

Mahmoo, Omar ;

Hinduja, Sanjay ;

Chen, Calvin K. ;

Damon, Lloyd ;

Abdulhaq, Haifaa .

CASE REPORTS IN HEMATOLOGY, 2020, 2020

← 1 2 →